Latest Breaking News On - Fda amp 39s office of prescription drug promotion issues its first untitled letter the year to novartis for misleading statement relating kisqali xae - Page 1 : comparemela.com

On January 18, 2024, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued its first untitled letter of the new year to Novartis Pharmaceuticals Corporation.

Kisqali qoDrug administrationOffice of prescription drug promotionOrganization for researchProduct communications that are consistentPharmaceuticals corporation novartisPrescription drug promotionPharmaceuticals corporationConsumer prescription drug advertisementsMajor statementNeutral mannerProduct communications that are consistent withUntitled letter kisqaliPromotional material kisqaliUnititled letter kisqaliCancer quality